Lorlatinib (Lorbrena) Approved for ALK+ NSCLC

Share this post

Another targeted agent is now available for use in patients with ALK+ metastatic non-small cell lung cancer (NSCLC) who have tried previous ALK-targeted therapies.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply